Clinical trial
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00096304 · Medical University of South Carolina, Other · Terminated
Key facts
| NCT number | NCT00096304 |
|---|---|
| Title | Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer |
| Lead sponsor | Medical University of South Carolina, Other |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, epirubicin hydrochloride |
| Enrollment | 36 |
| Start date | Jun 8, 2004 |
| Primary completion | Sep 6, 2006 |
| Completion | Nov 30, 2007 |
| First posted | Nov 9, 2004 |
| Last update posted | Apr 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: